46 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag https://www.zacks.com/stock/news/2202226/merck-mrk-daiichi-sankyo-s-lung-cancer-adc-gets-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202226 Dec 26, 2023 - Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now https://www.zacks.com/stock/news/2207963/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2207963 Jan 09, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152 Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
Q4 Earnings Season Scorecard and Fresh Analyst Reports for Amazon, Home Depot & Merck https://www.zacks.com/commentary/2214056/q4-earnings-season-scorecard-and-fresh-analyst-reports-for-amazon-home-depot-merck?cid=CS-ZC-FT-research_daily-2214056 Jan 23, 2024 - Today's Research Daily features a real-time update on the Q4 earnings season and updated reports on Amazon (AMZN), Home Depot (HD), Merck (MRK) & others.
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release https://www.zacks.com/stock/news/2215849/merck-mrk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215849 Jan 25, 2024 - Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214 Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861 Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580 Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry? https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567 Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study https://www.zacks.com/stock/news/2193811/exelixis-exel-collaborates-with-arcus-for-kidney-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193811 Dec 05, 2023 - Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

Pages: 12345

<Page 2>